These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21497883)

  • 1. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.
    Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M
    Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
    Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
    Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
    Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
    Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.
    Smalberg JH; Koehler E; Darwish Murad S; Plessier A; Seijo S; Trebicka J; Primignani M; de Maat MP; Garcia-Pagan JC; Valla DC; Janssen HL; Leebeek FW;
    Blood; 2011 Apr; 117(15):3968-73. PubMed ID: 21364191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
    Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
    Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
    [No Abstract]   [Full Text] [Related]  

  • 12. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
    Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
    Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2 46/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies.
    Li SL; Zhang PJ; Sun GX; Lu ZJ
    Ann Hematol; 2014 Nov; 93(11):1845-52. PubMed ID: 25015051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
    De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
    Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.